title: [Molecular pathology for breast cancer: Importance of the gene expression profile].
abstract: Gene expression arrays are currently used to guide therapy decisions in breast cancer. The indications for gene expression tests are especially important in the group of hormone receptor negative, HER2 positive tumors to decide whether endocrine therapy alone is sufficient or additional chemotherapy is necessary. In this group of luminal tumors conventional clinicopathological parameters are often not suitable to select patients who would benefit from an endocrine therapy alone. Gene expression tests can provide additional information and, therefore, support decision-making and avoid unnecessary chemotherapy. There are a variety of test systems available which poses the questions of which tests should be selected for which patients and how the test results should be evaluated in a direct comparison. This report provides information about three currently available gene expression tests (i.e. OncotypeDx®, Endopredict® and PAM50/Prosigna®), comments on similarities and differences and discusses the impact on therapy decisions. The focus of this article is on a discussion of clinical studies that have compared the different molecular tests in the same clinical study cohort. These investigations allow a first comparative evaluation of the various assays for breast cancer.
authors.affiliation: Institut für Pathologie, Charité Universitätsmedizin Berlin, Campus Mitte,Charitéplatz 1, 10117, Berlin, Deutschland, carsten.denkert@charite.de.
authors.forename: C
authors.initials: C
authors.lastname: Denkert
authors.forename: B M
authors.initials: BM
authors.lastname: Pfitzner
authors.forename: B I
authors.initials: BI
authors.lastname: Heppner
authors.forename: M
authors.initials: M
authors.lastname: Dietel
mesh_terms: D001940:Breast / Q000473:pathology; D001943:Breast Neoplasms / Q000235:genetics* / Q000473:pathology* / Q000628:therapy; D000068456:Clinical Studies as Topic; D015331:Cohort Studies; D005260:Female; D020869:Gene Expression Profiling; D006801:Humans; D025202:Molecular Diagnostic Techniques; D011237:Predictive Value of Tests; D011379:Prognosis
references.citation: BMC Cancer. 2014 Mar 13;14:177
references.pmid: 24625003
references.citation: Virchows Arch. 2014 Mar;464(3):283-91
references.pmid: 24487789
references.citation: J Clin Oncol. 2015 Mar 10;33(8):823-8
references.pmid: 25624431
references.citation: Breast Cancer Res Treat. 2011 May;127(1):133-42
references.pmid: 21221771
references.citation: Clin Cancer Res. 2014 Mar 1;20(5):1298-305
references.pmid: 24520097
references.citation: Breast Cancer Res. 2014 Apr 12;16(2):R38
references.pmid: 24725534
references.citation: J Clin Oncol. 2013 Aug 1;31(22):2783-90
references.pmid: 23816962
references.citation: Geburtshilfe Frauenheilkd. 2013 Sep;73(9):932-940
references.pmid: 24771945
references.citation: J Clin Oncol. 2009 Mar 10;27(8):1160-7
references.pmid: 19204204
references.citation: J Clin Oncol. 2010 Apr 10;28(11):1829-34
references.pmid: 20212256
references.citation: Clin Cancer Res. 2011 Sep 15;17(18):6012-20
references.pmid: 21807638
references.citation: Virchows Arch. 2012 Mar;460(3):251-9
references.pmid: 22371223
references.citation: J Clin Oncol. 2011 Nov 10;29(32):4273-8
references.pmid: 21990413
references.citation: J Clin Oncol. 2010 Apr 1;28(10):1671-6
references.pmid: 20065191
references.citation: Ann Oncol. 2014 Feb;25(2):339-45
references.pmid: 24347518
references.citation: Future Oncol. 2008 Oct;4(5):603-10
references.pmid: 18922117
references.citation: Clin Cancer Res. 2010 Nov 1;16(21):5222-32
references.pmid: 20837693
references.citation: Clin Breast Cancer. 2006 Oct;7(4):347-50
references.pmid: 17092406
references.citation: BMC Cancer. 2012 Oct 05;12:456
references.pmid: 23039280
references.citation: Eur J Cancer. 2013 May;49(8):1825-35
references.pmid: 23490655
references.citation: Ann Oncol. 2013 Mar;24(3):640-7
references.pmid: 23035151
references.citation: J Clin Oncol. 2006 Aug 10;24(23):3726-34
references.pmid: 16720680
references.citation: Lancet Oncol. 2013 Oct;14(11):1067-76
references.pmid: 24035531
references.citation: N Engl J Med. 2004 Dec 30;351(27):2817-26
references.pmid: 15591335
references.citation: Br J Cancer. 2013 Dec 10;109(12):2959-64
references.pmid: 24157828
references.citation: PLoS One. 2013 Jun 27;8(6):e68252
references.pmid: 23826382
references.citation: J Clin Oncol. 2011 Nov 20;29(33):4365-72
references.pmid: 22010013
references.citation: Virchows Arch. 2014 Oct;465(4):409-17
references.pmid: 25218890
references.citation: Lancet Oncol. 2010 Jan;11(1):55-65
references.pmid: 20005174
references.citation: J Clin Oncol. 2013 Nov 1;31(31):3997-4013
references.pmid: 24101045
references.citation: J Clin Oncol. 2008 Feb 10;26(5):729-35
references.pmid: 18258980
references.citation: PLoS One. 2013;8(3):e58483
references.pmid: 23505515
references.citation: Ann Oncol. 2014 Mar;25(3):754
references.pmid: 24500980
references.citation: J Clin Oncol. 2008 Sep 1;26(25):4063-71
references.pmid: 18678838
references.citation: J Clin Oncol. 2010 Jun 1;28(16):2784-95
references.pmid: 20404251
references.citation: J Clin Oncol. 2015 Mar 10;33(8):916-22
references.pmid: 25332252